Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has announced that its subsidiary, Watson Laboratories, Inc, has received approval from the FDA to market its over-the-counter nicotine polacrilex gum USP, coated mint flavor, in the 2mg and 4mg strengths.
Subscribe to our email newsletter
Nicotine polacrilex gum, coated mint flavor, is the generic equivalent of GlaxoSmithKline Consumer Healthcare’s Nicorette fresh mint gum, which is used as an aid to smoking cessation. Watson said that it will make the product available to customers in early January 2009.
Paul Bisaro, president and CEO of Watson, said: “The approval of our mint-flavored, coated nicotine gum is a significant addition to our line of generic smoking cessation products. We also have applications pending at FDA for additional flavors and look forward further enhancing our line of smoking cessation products.”